JP2025511002A5 - - Google Patents
Info
- Publication number
- JP2025511002A5 JP2025511002A5 JP2024557583A JP2024557583A JP2025511002A5 JP 2025511002 A5 JP2025511002 A5 JP 2025511002A5 JP 2024557583 A JP2024557583 A JP 2024557583A JP 2024557583 A JP2024557583 A JP 2024557583A JP 2025511002 A5 JP2025511002 A5 JP 2025511002A5
- Authority
- JP
- Japan
- Prior art keywords
- amino acid
- seq
- acid sequence
- chain comprises
- cancer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263325437P | 2022-03-30 | 2022-03-30 | |
| US63/325,437 | 2022-03-30 | ||
| PCT/EP2023/058418 WO2023187130A1 (en) | 2022-03-30 | 2023-03-30 | Activatable bispecific anti-cd3 and anti-pd-l1 proteins and uses thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2025511002A JP2025511002A (ja) | 2025-04-15 |
| JP2025511002A5 true JP2025511002A5 (https=) | 2026-04-02 |
Family
ID=86052101
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024557583A Pending JP2025511002A (ja) | 2022-03-30 | 2023-03-30 | 活性化可能な二重特異性抗ｃｄ３および抗ｐｄ－ｌ１タンパク質ならびにその使用 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20250109206A1 (https=) |
| EP (1) | EP4499232A1 (https=) |
| JP (1) | JP2025511002A (https=) |
| KR (1) | KR20240163741A (https=) |
| CN (1) | CN119677780A (https=) |
| AU (1) | AU2023246985A1 (https=) |
| CA (1) | CA3246893A1 (https=) |
| IL (1) | IL315768A (https=) |
| MX (1) | MX2024011776A (https=) |
| WO (1) | WO2023187130A1 (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN121851177A (zh) * | 2023-12-11 | 2026-04-14 | 合肥天港免疫药物有限公司 | 双特异性抗体及其应用 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT1907424E (pt) | 2005-07-01 | 2015-10-09 | Squibb & Sons Llc | Anticorpos monoclonais humanos para o ligando 1 de morte programada (pd-l1) |
| EP2789630A1 (en) | 2013-04-09 | 2014-10-15 | EngMab AG | Bispecific antibodies against CD3e and ROR1 |
| CN110590955B (zh) * | 2018-09-17 | 2021-05-18 | 北京盛诺基医药科技股份有限公司 | 一种双特异性抗体 |
| GB201906685D0 (en) * | 2019-05-13 | 2019-06-26 | Ultrahuman Six Ltd | Activatable protein constructs and uses thereof |
-
2023
- 2023-03-30 IL IL315768A patent/IL315768A/en unknown
- 2023-03-30 KR KR1020247035680A patent/KR20240163741A/ko active Pending
- 2023-03-30 AU AU2023246985A patent/AU2023246985A1/en active Pending
- 2023-03-30 EP EP23717433.9A patent/EP4499232A1/en active Pending
- 2023-03-30 CA CA3246893A patent/CA3246893A1/en active Pending
- 2023-03-30 WO PCT/EP2023/058418 patent/WO2023187130A1/en not_active Ceased
- 2023-03-30 JP JP2024557583A patent/JP2025511002A/ja active Pending
- 2023-03-30 CN CN202380038600.4A patent/CN119677780A/zh active Pending
-
2024
- 2024-09-19 US US18/889,571 patent/US20250109206A1/en active Pending
- 2024-09-25 MX MX2024011776A patent/MX2024011776A/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11286311B2 (en) | CH3 domain variant pair inducing formation of heterodimer of heavy chain constant region of antibody at high efficiency, method for preparing same, and use thereof | |
| CN111148761B (zh) | 多特异性抗体及其制备和使用方法 | |
| CN103687879B (zh) | 多价抗原结合fv分子 | |
| US10047163B2 (en) | Multispecific constructs | |
| DK2371866T3 (en) | Multivalent antigen-binding Fv molecule | |
| CN116731180A (zh) | 抗ror1抗体及其制备和使用方法 | |
| Chen et al. | A bispecific antibody targeting HER2 and PD-L1 inhibits tumor growth with superior efficacy | |
| EP3177646A1 (en) | Cd3 binding domain | |
| CN104271602A (zh) | 双特异性抗体 | |
| CN117946277A (zh) | 多特异性抗体及其制备和使用方法 | |
| CN116041530A (zh) | 多特异性抗体及其制备和使用方法 | |
| JP2022550243A (ja) | 抗ｐｄ－１抗体及びその使用 | |
| JP7675818B2 (ja) | 抗クローディン－１８．２抗体及びその抗体薬物複合体 | |
| JP2022546002A (ja) | ４価の対称型二重特異性抗体 | |
| KR20240046224A (ko) | 이중특이성 항체 및 그 용도 | |
| JP7738914B2 (ja) | ＴｒｉＡｘ抗体の組成、その製造方法及び使用方法 | |
| JP7633259B2 (ja) | ＴＧＦ－βＲＩＩ結合タンパク質 | |
| JP2025511002A5 (https=) | ||
| CA3238406A1 (en) | Bispecific antibody and use thereof | |
| JP7510209B2 (ja) | ヘルパーＴ細胞ＴＧＦ－βシグナルを特異的に中和する二重特異性抗体、その薬物組成物およびその使用 | |
| JP2025504955A5 (https=) | ||
| RU2024108736A (ru) | Биспецифическое антитело к lag3, фармацевтическая композиция и применение | |
| WO2024174743A1 (zh) | 一种靶向αvβ3和CD47的双功能融合蛋白以及其应用 | |
| WO2024054418A1 (en) | Sequence optimization of a pd1 blocking antibody | |
| HK40076734A (en) | Composition of triax antibodies and method of making and using thereof |